



Enabling Large-Scale Analysis of Electronic Health Records in Europe by standardizing to a Common Data Model

#### **Peter Rijnbeek**

Associate Professor Health Data Science
Department of Medical Informatics
Erasmus MC Rotterdam
The Netherlands













## GENERATING RELIABLE EVIDENCE AT SCALE



How can we generate reliable evidence at a large scale, i.e. on many data sources in Europe for many research questions?



## NEED TO IMPROVE INTEROPERABILITY OF HEALTH DATA



The data...

























#### What will it require?









**Data network** 

**Strong community** 

Data interoperability

Standardised analytics



### **EHDEN: VISION AND MISSION**



#### Vision

The European Health Data & Evidence Network (EHDEN) aspires to be the trusted observational research ecosystem to enable better health decisions, outcomes and care

#### Mission

Our mission is to provide a new paradigm for the discovery and analysis of health data in Europe, by building a large-scale, federated network of data sources standardised to a common data model



#### **EHDEN CONSORTIUM**

#### Innovative Medicines Initiative Project



Start date: 1 Nov 2018 **End date**: 30 Apr 2024 **Duration**: 66 months



22 partners



Almost €29 million

#### Universities, public bodies and research organisations



Academic coordinator











#### Small to medium-sized companies



#### Non-for-profit organisations





#### **EFPIA & Associated partners**





















AstraZeneca












## GENERATING RELIABLE EVIDENCE USING THE OMOP CDM





The OMOP Common Data Model enables standardised analytics to generate reliable evidence







www.ehden.eu









# **DESIRED ATTRIBUTES FOR RELIABLE EVIDENCE**




Desired attribute	Question	Researcher	Data	Analysis		Result
Repeatable	Identical	Identical	Identical	Identical	=	Identical
Reproducible	Identical	Different	Identical	Identical	=	Identical
Replicable	Identical	Same or	Similar	Identical	=	Similar
		different				
Generalizable	Identical	Same or different	Different	Identical	=	Similar
Robust	Identical	Same or different	Same or different	Different	=	Similar

#### How a cdm + common analytics can support reproducibility



Desired attribute	Question	Researcher	Data	Analysis		Result
Reproducible	Identical	Different	Identical	Identical	=	Identical

Patient-level data in source system/schema



- Use of common data model splits the journey into two segments: 1) data standardization, 2) analysis execution
- ETL specification and source code can be developed and evaluated separately from analysis design
- CDM creates opportunity for re-use of data step and analysis step






## **CHALLENGES TO ACHIEVE REPLICATION**



Desired attribute	Question	Researcher	Data	Analysis		Result
Replicable	Identical	Same or different	Similar	Identical	=	Similar



If analysis procedure is not identical across sources, how do you determine if any differences observed are due to data vs. analysis?








Desired attribute	Question	Researcher	Data	Analysis		Result
Replicable	Identical	Same or different	Similar	Identical	=	Similar
Source 1	5		Source 1 CDM			Similar evidence
Source i	A B		Source i CDM			Reliable vidence
Source n	<b>6</b>		Source n CDM			Similar evidence



#### How a common data model + common analytics can support robustness, → □




Desired attribute	Question	Researcher	Data	Analysis		Result
Robust	Identical	Same or different	Same or different	Different	=	Similar
						M





### **DEEP INFORMATION MODEL: OMOP CDM**







## **OHDSI's GLOBAL RESEARCH COMMUNITY**






- More than 2,100 collaborators across six continents.
- There are currently 166 databases in the network, spread out over 23 different nations, with 578 million distinct
  patients and 2.7 billion deidentified patient records across all databases who reported to be part of the network.
- The community developed and manages 20 open-source applications to aid in observational research, and
- has 25 workgroups engaged in research around various healthcare topics.






## AFTER THREE CALLS WE INCLUDED 61 DATA PARTNERS FROM 16 COUNTRIES







Large interest in recent call (budget 5 million Euro) with 55 applications from 20 countries (not shown in image above).











## AFTER TWO CALLS EHDEN HAS CERTIFIED 26 SMEs IN 14 COUNTRIES











- FDA awarded a \$10 million contract to OHDSI in 2020 to provide support to the BEST program around vaccine surveillance.
- Multiple studies for EMA using OMOP-CDM.
- Multiple European projects build on OMOP-CDM.
- Global uptake with regional chapters (US, Europe, Australia, China, Japan, South Korea, Singapore, etc.)
- Large body of scientific output generated by OHDSI community, e.g. on COVID-19.



We demonstrated that a collective effort to improve the interoperability of health data works and has impact!




### **N**EED MORE INFORMATION?











https://book.ohdsi.org

https://academy.ehden.eu

https://ohdsi-europe.org



www.ehden.eu



@IMI\_EHDEN



IMI EHDEN



github.com/EHDEN







This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.